Synrx patents new PARG inhibitors for triple-negative breast cancer
April 24, 2025
Hangzhou Synrx Therapeutics Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of triple-negative breast cancer.